Author:
Zhao Shui-Ai,Ning Bo-Tao,Mao Jian-Hua
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference12 articles.
1. Tserenpuntsag B, Chang HG, Smith PF, Morse DL. Hemolytic uremic syndrome risk and Escherichia coli O157:H7. Emerg Infect Dis 2005;11:1955–1957.
2. Rock G, Kolajova M, Faught C, Zimmerman D. Identification of plasma antifibrin/fibrinogen antibodies in a patient with hemolytic uremic syndrome. Blood Coagul Fibrinolysis 2006;17:539–544.
3. Zhang Y, Meng Q, Zhou C. The epidemic survey of children with hemolytic uremic syndrome (HUS), analysis of the death patients and therapeutic advance in 35 years in Beijing Children’s Hospital. J Clin Pediatr (Chinese) 2003;21:545–548. [In Chinese]
4. Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, et al. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Methods Mol Biol 2014;1100:237–247.
5. Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 2016;68:84–93.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献